Abstract: The present invention relates to novel ABC1 polypeptides and nucleic acid molecules encoding the same. The invention also relates to recombinant vectors, host cells, and compositions comprising ABC1 polynucleotides, as well as to methods for producing ABC1 polypeptides. The invention also relates to antibodies that bind specifically to ABC1 polypeptides. In addition, the invention relates to methods for increasing cholesterol efflux as well as to methods for increasing ABC1 expression and activity. The present invention further relates to methods for identifying compounds that modulate the expression of ABC1 and methods for detecting the comparative level of ABC1 polypeptides and polynucleotides in a mammalian subject. The present invention also provides kits and compositions suitable for screening compounds to determine the ABC1 expression modulating activity of the compound, as well as kits and compositions suitable to determine whether a compound modulates ABC1-dependent cholesterol efflux.
Type:
Grant
Filed:
June 16, 2000
Date of Patent:
December 28, 2004
Assignee:
CV Therapeutics
Inventors:
Richard M. Lawn, David Wade, Michael Garvin, John F. Oram
Abstract: A myocardial imaging method that is accomplished by administering one or more adenosine A2A adenosine receptor agonist to a human undergoing myocardial imaging.
Abstract: This invention encompasses a substantially homogeneous lipid chemoattractant released from stressed mammalian tissue which is a neutral lipid which is acid labile and stable to base and is stable in boiling water. This lipid recruits macrophages but not neutrophils to stressed tissue. The invention also encompasses a method for detecting injured tissue by detecting the presence of the above described lipid chemoattractant in body fluids such as urine, serum and saliva. The invention also includes a method for reducing recruitment of macrophages to injured tissue by reducing the amount of the above lipid chemoattractant or by blocking the interaction of this lipid chemoattractant with its macrophage binding site. The addition of this lipid chemoattractant to injured skin tissue promotes healing.
Type:
Grant
Filed:
May 9, 1997
Date of Patent:
February 9, 1999
Assignee:
CV Therapeutics
Inventors:
George F. Schreiner, Louis G. Lange, III
Abstract: A substituted N.sup.6 -oxa, thia, thioxa and azacycloalkyl substituted adenosine derivative and a method for using the composition as an A.sub.1 heart adenosine receptor.
Type:
Grant
Filed:
August 27, 1996
Date of Patent:
August 4, 1998
Assignee:
CV Therapeutics
Inventors:
Robert T. Lum, Jurg R. Pfister, Steven R. Schow, Michael M. Wick, Marek G. Nelson, George F. Schreiner
Abstract: This invention encompasses a substantially homogeneous lipid chemoattractant released from stressed mammalian tissue which is a neutral lipid which is acid labile and stable to base and is stable in boiling water. This lipid recruits macrophages but not neutrophils to stressed tissue. The invention also encompasses a method for detecting injured tissue by detecting the presence of the above described lipid chemoattractant in body fluids such as urine, serum and saliva. The invention also includes a method for reducing recruitment of macrophages to injured tissue by reducing the amount of the above lipid chemoattractant or by blocking the interaction of this lipid chemoattractant with its macrophage binding site. The addition of this lipid chemoattractant to injured skin tissue promotes healing.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
September 2, 1997
Assignee:
CV Therapeutics
Inventors:
George F. Schreiner, Louis G. Lange, III
Abstract: Intestinal cell endogenous heparin mediated absorption of cholesterol or fatty acids in mammals is inhibited through the oral administration of heparin, an active heparin subfraction or heparinase. Suppression of cholesterol esterase-mediated absorption in humans can be inhibited by soluble heparin by two mechanisms, i.e. displacement of the enzyme from the intestinal cell membrane and inhibition of enzymatic activity of the displaced enzyme.
Type:
Grant
Filed:
September 26, 1994
Date of Patent:
July 4, 1995
Assignee:
CV Therapeutics
Inventors:
Louis G. Lange, III, Curtis A. Spilburg, Paula M. Kinnunen